Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 15 of the 26 sources its claims cite were checked for support.

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

Open access

Abstract

Summary Background Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide in adults. Pharmacological and non-pharmacological treatments are available; however, because of inadequate resources, antidepressants are used more frequently than psychological interventions. Prescription of these agents should be informed by the best available evidence. Therefore, we aimed to update and expand our previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder. Methods We did a systematic review and network meta-analysis. We searched Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS database, MEDLINE, MEDLINE In-Process, PsycINFO, the websites of regulatory agencies, and international registers for published and unpublished, double-blind, randomised controlled trials from their inception to Jan 8, 2016. We included placebo-controlled and head-to-head trials of 21 antidepressants used for the acute treatment of adults (≥18 years old and of both sexes) with major depressive disorder diagnosed according to standard operationalised criteria. We excluded quasi-randomised trials and trials that were incomplete or included 20% or more of participants with bipolar disorder, psychotic depression, or treatment-resistant depression; or patients with a serious concomitant medical illness. We extracted data following a predefined hierarchy. In network meta-analysis…

Overview

CoChat Summary

TL;DR

In this systematic review and network meta-analysis of 522 double-blind randomised trials (116,477 participants), all 21 antidepressants were more efficacious than placebo for acute treatment of adults with major depressive disorder, though effect sizes were mostly modest. Some drugs showed more favourable efficacy/acceptability profiles, but many comparative estimates had wide credible intervals and certainty of evidence was moderate to very low.

Key findings

  • Across 522 trials and 116,477 participants, all antidepressants were more effective than placebo, with ORs ranging from 2·13 (95% CrI 1·89–2·41) for amitriptyline to 1·37 (1·16–1·63) for reboxetine.
  • For acceptability, only agomelatine (OR 0·84, 95% CrI 0·72–0·97) and fluoxetine (0·88, 0·80–0·96) were associated with fewer dropouts than placebo, whereas clomipramine was worse than placebo (1·30, 1·01–1·68).
  • In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other antidepressants (ORs 1·19–1·96), while fluoxetine, fluvoxamine, reboxetine, and trazodone were least efficacious (0·51–0·84). For acceptability, agomelatine, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine were more tolerable (0·43–0·77), while amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine had the highest dropout rates (1·30–2·32).
  • Risk of bias was high in 46 (9%) of 522 trials, moderate in 380 (73%), and low in 96 (18%); certainty of evidence was moderate to very low, and differences between active drugs ranged from 1·15 to 1·55 for efficacy and 0·64 to 0·83 for acceptability, with wide CrIs on most comparative analyses.

Methods

  • Systematic review and network meta-analysis; searched Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS, MEDLINE, MEDLINE In-Process, PsycINFO, regulatory agency websites, and international registers from inception to Jan 8, 2016.
  • Included double-blind randomised controlled trials of 21 antidepressants or placebo as oral monotherapy for acute treatment of adults (≥18 years, both sexes) with major depressive disorder diagnosed by standard operationalised criteria; excluded quasi-randomised trials and trials with ≥20% bipolar disorder, psychotic depression, treatment-resistant depression, or serious concomitant medical illness.
  • Primary outcomes were efficacy (response rate, ≥50% reduction on a standardised observer-rating scale) and acceptability (all-cause treatment discontinuation); estimated summary ORs using random-effects pairwise and network meta-analysis, assessed risk of bias and GRADE certainty, and ranked treatments with SUCRA; PROSPERO CRD42012002291.

Limitations

  • Stated by the paper: many comparisons were low or very low certainty (e.g., involving amitriptyline, bupropion, venlafaxine); many trials did not report adequate information about randomisation and allocation concealment; analyses covered only average treatment effects and could not investigate individual-patient modifiers; patients with psychotic or treatment-resistant depression were excluded; trials were short duration; unpublished data were incomplete for some drugs; no formal cost-effectiveness analysis; and results cannot guide next-step choices after first treatment failure.
  • Evident from the text: most comparative analyses had wide credible intervals; 9% of trials were high risk of bias and 73% moderate; network meta-analysis depends on transitivity and consistency assumptions; and placebo-controlled versus head-to-head results differed, including a novelty effect favouring experimental drugs.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)32802-7

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study selection process RCTs=randomised controlled trials. *Industry websites, contact with authors, and trial registries. The total number of unpublished records is the total number of results for each drug and on each unpublished database source. †522 RCTs corresponded to 814 treatment groups.
Figure 1 Study selection process RCTs=randomised controlled trials. *Industry websites, contact with authors, and trial registries. The total number of unpublished records is the total number of results for each drug and on each unpublished database source. †522 RCTs corresponded to 814 treatment groups.CC BY · PubMed Central
Figure 2 Network meta-analysis of eligible comparisons for efficacy (A) and acceptability (B) Width of the lines is proportional to the number of trials comparing every pair of treatments. Size of every circle is proportional to the number of randomly assigned participants (ie, sample size).
Figure 2 Network meta-analysis of eligible comparisons for efficacy (A) and acceptability (B) Width of the lines is proportional to the number of trials comparing every pair of treatments. Size of every circle is proportional to the number of randomly assigned participants (ie, sample size).CC BY · PubMed Central
Figure 3 Forest plots of network meta-analysis of all trials for efficacy (A) and acceptability (B) Antidepressants were compared with placebo, which was the reference compound. OR=odds ratio. CrI=credible interval.
Figure 3 Forest plots of network meta-analysis of all trials for efficacy (A) and acceptability (B) Antidepressants were compared with placebo, which was the reference compound. OR=odds ratio. CrI=credible interval.CC BY · PubMed Central
Figure 4 Head-to-head comparisons for efficacy and acceptability of the 21 antidepressants Drugs are reported in alphabetical order. Data are ORs (95% CrI) in the column-defining treatment compared with the row-defining treatment. For efficacy, ORs higher than 1 favour the column-defining treatment (ie, the first in alphabetical order). For acceptability, ORs lower than 1 favour the first drug in alphabetical order. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. Significant results are in bold and underscored. The certainty of the evidence (according to GRADE) was incorporated in this figure (appendix pp 231–65). OR=odds ratio. CrI=credible interval. Agom=agomelatine. Amit=amitriptyline. Bupr=bupropion. Cita=citalopram. Clom=clomipramine. Dulo=duloxetine. Esci=escitalopram. Fluo=fluoxetine. Fluv=fluvoxamine. Miln=milnacipran. Mirt=mirtazapine. Nefa=nefazodone. Paro=paroxetine. Rebo=reboxetine. Sert=sertraline. Traz=trazodone. Venl=venlafaxine. Vort=vortioxetine. *Moderate quality of evidence. †Low quality of evidence. ‡Very low quality of evidence.
Figure 4 Head-to-head comparisons for efficacy and acceptability of the 21 antidepressants Drugs are reported in alphabetical order. Data are ORs (95% CrI) in the column-defining treatment compared with the row-defining treatment. For efficacy, ORs higher than 1 favour the column-defining treatment (ie, the first in alphabetical order). For acceptability, ORs lower than 1 favour the first drug in alphabetical order. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. Significant results are in bold and underscored. The certainty of the evidence (according to GRADE) was incorporated in this figure (appendix pp 231–65). OR=odds ratio. CrI=credible interval. Agom=agomelatine. Amit=amitriptyline. Bupr=bupropion. Cita=citalopram. Clom=clomipramine. Dulo=duloxetine. Esci=escitalopram. Fluo=fluoxetine. Fluv=fluvoxamine. Miln=milnacipran. Mirt=mirtazapine. Nefa=nefazodone. Paro=paroxetine. Rebo=reboxetine. Sert=sertraline. Traz=trazodone. Venl=venlafaxine. Vort=vortioxetine. *Moderate quality of evidence. †Low quality of evidence. ‡Very low quality of evidence.CC BY · PubMed Central
Figure 5 Two-dimensional graphs about efficacy and acceptability in all studies (A) and head-to-head (B) studies only Data are reported as ORs in comparison with reboxetine, which is the reference drug. Error bars are 95% CrIs. Individual drugs are represented by different coloured nodes. Desvenlafaxine, levomilnacipran, and vilazodone were not included in the head-to-head analysis because these three antidepressants had only placebo-controlled trials. ORs=odds ratios. 1=agomelatine. 2=amitriptyline. 3=bupropion. 4=citalopram. 5=clomipramine. 6=desvenlafaxine. 7=duloxetine. 8=escitalopram. 9=fluoxetine. 10=fluvoxamine. 11=levomilnacipran. 12=milnacipran. 13=mirtazapine. 14=nefazodone. 15=paroxetine. 16=reboxetine. 17=sertraline. 18=trazodone. 19=venlafaxine. 20=vilazodone. 21=vortioxetine. 22=placebo.
Figure 5 Two-dimensional graphs about efficacy and acceptability in all studies (A) and head-to-head (B) studies only Data are reported as ORs in comparison with reboxetine, which is the reference drug. Error bars are 95% CrIs. Individual drugs are represented by different coloured nodes. Desvenlafaxine, levomilnacipran, and vilazodone were not included in the head-to-head analysis because these three antidepressants had only placebo-controlled trials. ORs=odds ratios. 1=agomelatine. 2=amitriptyline. 3=bupropion. 4=citalopram. 5=clomipramine. 6=desvenlafaxine. 7=duloxetine. 8=escitalopram. 9=fluoxetine. 10=fluvoxamine. 11=levomilnacipran. 12=milnacipran. 13=mirtazapine. 14=nefazodone. 15=paroxetine. 16=reboxetine. 17=sertraline. 18=trazodone. 19=venlafaxine. 20=vilazodone. 21=vortioxetine. 22=placebo.CC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 0 Not valid · 10 Not checked · 93 Own results and interpretations

49 more claims

Create a free account to see all 118 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 39
  • It may state two separate claims as one. 33

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

27 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 33 references

Cited by

See all 3,541

Metadata

Authors
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R.
Affiliations
  • Oxford Health NHS Foundation Trust (GB)
  • Kyoto University (JP)
  • University of Bern (CH)
  • Inserm (FR)
  • Warneford Hospital (GB)
  • Technical University of Munich (DE)
  • Oregon Health & Science University (US)
  • University of Bristol (GB)
  • Stanford University (US)
Corresponding author
Cipriani, Andrea
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-04
Volume
391
Issue
10128
Pages
1357-1366
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2788337440
Cited by
3,541
References
33
Citations by year
2026: 383 · 2025: 472 · 2024: 469 · 2023: 426 · 2022: 399 · 2021: 423 · 2020: 475 · 2019: 322 · 2018: 163
FWCI
40.44
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • FOCUS The Journal of Lifelong Learning in Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
  • Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Explore Bristol Research (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
  • National Institute for Health and Care Research (BRC‐1215‐20005, NF-SI-0617-10145)
  • Japan Society for the Promotion of Science (17K19808, 16K09033)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
major depressive disorder, antidepressants, acute treatment, antidepressant efficacy, treatment discontinuation, placebo response, amitriptyline, reboxetine, agomelatine, fluoxetine, venlafaxine, escitalopram, mirtazapine, paroxetine, sertraline, bupropion
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Patient Dropouts, Randomized Controlled Trials as Topic, Treatment Outcome, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(17)32802-7
The paper
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(17)32802-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.